Testing a new drug combo for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with follicular lymphoma (a slow-growing type of lymphoma).
- You have not had any previous treatment for your lymphoma.
- Your doctor says you need treatment now, and your lymphoma is causing symptoms or affecting your health.
- You are in good enough health to receive treatment, with normal liver, kidney, blood, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
This trial tests a new drug called surovatamig against the usual treatment (radiation, sometimes with rituximab) for people with early-stage follicular lymphoma that hasn't been treated yet. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
This study compares two drug combinations for people newly diagnosed with follicular lymphoma. One group gets zanubrutinib plus lenalidomide, and the other gets lenalidomide plus rituximab. The goal is to see which combination works better with acceptable side effects.
Hear when a new Untreated Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.